MARKET

PLUR

PLUR

PLURILOCK SEC INC
NASDAQ
5.72
+0.10
+1.78%
Closed 16:00 06/12 EDT
OPEN
5.50
PREV CLOSE
5.62
HIGH
5.74
LOW
5.50
VOLUME
1.67K
TURNOVER
0
52 WEEK HIGH
8.56
52 WEEK LOW
3.449
MARKET CAP
30.82M
P/E (TTM)
-1.3589
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PLUR last week (0603-0607)?
Weekly Report · 2d ago
Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
Benzinga · 6d ago
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
The U.S. National Institute of Allergy and Infectious Diseases has exercised its option for year two of the three-year contract it entered into with Pluri in July 2023. The NIAID will provide $1.4 million for the Company to develop the PLX-R18 cell therapy. Pluri is developing a potential treatment for the acute radiation syndrome.
Barchart · 06/06 05:45
Weekly Report: what happened at PLUR last week (0527-0531)?
Weekly Report · 06/03 10:53
Weekly Report: what happened at PLUR last week (0520-0524)?
Weekly Report · 05/27 10:57
Weekly Report: what happened at PLUR last week (0513-0517)?
Weekly Report · 05/20 10:51
Weekly Report: what happened at PLUR last week (0506-0510)?
Weekly Report · 05/13 10:59
Pluri Inc. Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 18:04
More
About PLUR
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Webull offers Pluri Inc stock information, including NASDAQ: PLUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLUR stock methods without spending real money on the virtual paper trading platform.